Adenosine closes the K\(^+\) channel \(K_{\text{Ca}3.1}\) in human lung mast cells and inhibits their migration via the adenosine \(A_{2A}\) receptor

S. Mark Duffy, Glenn Cruse, Christopher E. Brightling and Peter Bradding

Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester, Leicester, UK

Human lung mast cells (HLMC) express the \(Ca^{2+}\)-activated \(K^+\) channel \(K_{\text{Ca}3.1}\), which opens following IgE-dependent activation. This hyperpolarises the cell membrane and potentiates both \(Ca^{2+}\) influx and degranulation. In addition, blockade of \(K_{\text{Ca}3.1}\) profoundly inhibits HLMC migration to a variety of diverse chemotactic stimuli. \(K_{\text{Ca}3.1}\) activation is attenuated by the \(\beta_2\)adrenoceptor through a \(G_{\alpha}\)-coupled mechanism independent of cyclic AMP. Adenosine is an important mediator that both attenuates and enhances HLMC mediator release through the \(G_{\alpha}\)-coupled \(A_{2A}\) and \(A_{2B}\) adenosine receptors, respectively. We show that at concentrations that inhibit HLMC degranulation (10\(^{-5}\)–10\(^{-3}\) M), adenosine closes \(K_{\text{Ca}3.1}\) both dose-dependently and reversibly. \(K_{\text{Ca}3.1}\) suppression by adenosine was reversed partially by the selective adenosine \(A_{2A}\) receptor antagonist ZM241385 but not by the \(A_{2B}\) Receptor antagonist MRS1754, and the effects of adenosine were mimicked by the selective \(A_{2A}\) Receptor agonist CGS21680. Adenosine also opened a depolarising current carried by non-selective cations. As predicted from the role of \(K_{\text{Ca}3.1}\) in HLMC migration, adenosine abolished HLMC chemotaxis to asthmatic airway smooth muscle-conditioned medium. In summary, the \(G_{\alpha}\)-coupled \(A_{2A}\) receptor closes \(K_{\text{Ca}3.1}\), providing a clearly defined mechanism by which adenosine inhibits HLMC migration and degranulation. \(A_{2A}\) receptor agonists with channel-modulating function may be useful for the treatment of mast cell-mediated disease.

Introduction

Mast cells are bone marrow-derived cells that are present in all organs throughout the human body, both at mucosal surfaces and within connective tissues. Mast cells play a major role in tissue homeostasis, host defence and the pathophysiology of many diverse diseases [1]. They are best known for their role in asthma and allergy through the ability of allergen to cross-link allergen-specific IgE bound to the high-affinity IgE receptor (FceRI) expressed on the mast cell surface [2, 3]. FceRI cross-linking triggers a complex signalling cascade, which culminates in the influx of extracellular \(Ca^{2+}\) and the release of a plethora of autacoid mediators, proteases and cytokines [1]. In addition, the mast cell is activated by many non-immunological stimuli such as cytokines [4], Ig free light chains [5], Toll-like receptor ligands [6–8] and proteases [9], which contribute to the activation of mast cells in response to a variety of tissue insults. In many diseases mast cells re-locate to specific compartments within tissue, such as the airway smooth muscle [10] and submucosal glands [11] in asthma. Drugs that target this migration may prove particularly effective in the treatment of mast cell-mediated disease.

Ion channels are emerging as interesting targets for the modulation of biological function in both inflam-
matory and structural non-excitable cells [12, 13].

Following FcεRI cross-linking, human lung mast cells (HLMC) open the intermediate conductance Ca^{2+}-activated K^{+} channel K_{Ca3.1} (also known as IK_{Ca1}/K_{Ca4}), which hyperpolarises the cell membrane potential to around −45 mV [14]. The negative cell membrane potential generated by these open K^{+} channels enhances HLMC Ca^{2+} influx and histamine release [14, 15] due to both the favourable electrical driving force for Ca^{2+} entry and enhanced Ca^{2+} conductance through store-operated Ca^{2+} channels that mediate Ca^{2+} influx following cell activation [16]. Also of great interest, blockade of K_{Ca3.1} virtually abolishes HLMC migration to a number of diverse chemotactic stimuli including asthmatic airway smooth muscle-conditioned medium [17].

K_{Ca3.1} in HLMC is closed by the β_{2}-adrenoceptor agonist salbutamol [18]. This occurs through a G_{as} G-protein-coupled mechanism that is independent of cAMP and explains in part how β_{2}-adrenoceptor stimulation translates into reduced secretion. Whether this is specific to the β_{2}-adrenoceptor or whether K_{Ca3.1} is modulated by other G protein-coupled receptors (GPCR) is therefore of great interest. Adenosine is a purine nucleoside generated by numerous cell types in response to cell stress and hypoxia. It modulates human mast cell secretion through the adenosine A_{2A} and A_{2B} GPCR and is of particular relevance to asthma [19–21]. The A_{2A} receptor signals via adenylate cyclase, involving G_{as} coupling, and A_{2B} signals via multiple mechanisms including adenylate cyclase, diacylglycerol and inositol triphosphate, involving both G_{as} and G_{aq} coupling [22]. A_{2B} signalling has additionally been show to be mediated independently of G proteins via PDZ-containing proteins. The effects of adenosine on HLMC both in vitro and in vivo are complex; at relatively low concentrations in vitro (10^{-6} M), adenosine is said to potentiate IgE-dependent secretion, but the reported effects vary widely [23–27]. Because adenosine induces cytokine secretion from a human mast cell line through the A_{2B} receptor [28], it is also thought that potentiation of secretion from HLMC is mediated via the A_{2B} receptor, but this is not proven. In contrast, at higher concentrations of adenosine (10^{-5} to 10^{-3} M), there is more consistent dose-dependent and profound inhibition of secretion [23, 24, 27, 29], mediated predominantly via the A_{2A} receptor [30]. In vivo, adenosine induces histamine and tryptase release from resident mast cells when delivered as an aerosol to the airways [31] and induces bronchoconstriction in subjects with asthma but not normal subjects. It is thought that these in vivo effects are mediated directly on mast cells, although it remains possible that intermediaries and neural reflexes are also involved [32].

Since K_{Ca3.1} in HLMC is closed by the G_{as}-coupled β_{2}-adrenoceptor, we hypothesised that activation of the A_{2A} G_{as}-coupled adenosine receptor would also close K_{Ca3.1} in these cells. Furthermore, if adenosine was to close K_{Ca3.1}, then it should inhibit HLMC chemotaxis. To test this hypothesis, we used the patch-clamp technique to investigate the effects of adenosine on HLMC ion channel function and investigated the effect of adenosine on HLMC migration in response to asthmatic airway smooth muscle-conditioned medium.

**Results**

**Inhibition of HLMC IgE-dependent histamine release by adenosine**

Adenosine alone had no effect on mast cell histamine release in the dose range 10^{-10} to 10^{-3} M (Fig. 1A). In the presence of anti-IgE, no potentiation of IgE-dependent histamine release by adenosine was evident with either maximal (1:1000 anti-IgE) or sub-maximal (1:30 000 anti-IgE) activation (Fig. 1B). However, there was dose-dependent inhibition of IgE-dependent histamine release over the dose range 10^{-6} to 10^{-3} M adenosine (Fig. 1B). Half-maximal suppression (IC_{50}) of histamine release occurred at an adenosine concentration of 73.8±23.5 μM. This inhibition of histamine release by adenosine was significantly attenuated in the presence of the adenosine A_{2A} receptor antagonist ZM241385 (Fig. 1C).

**Adenosine alone does not open K_{Ca3.1} but opens an outwardly rectifying non-selective cation current**

Adenosine at around 10^{-6} M has been reported to enhance IgE-dependent histamine release, although this was not the case in our hands. We therefore first examined the effects of adenosine alone in the concentration range 10^{-7} to 10^{-3} M to assess whether it might open K_{Ca3.1}, but it did not. However, adenosine at 10^{-4} and 10^{-3} M did open a novel strongly outwardly rectifying current (Fig. 2A). With an adenosine concentration of 10^{-3} M, this current appeared in 15/18 cells tested (n=6 donors) within 30 s of adding adenosine to the recording chamber, consistently reached maximal amplitude over the course of a few seconds, and typically “ran-down” completely over 20 s. This sequence could be re-initiated on further application of adenosine, but the transient nature of the current prevented detailed electrophysiological characterisation. In cells in which the outward current appeared, adenosine at a concentration of 10^{-3} M increased membrane current measured at +100 mV from 13.0±3.4 pA to 153.0±27.0 pA (n=15), with a positive shift in reversal potential from −14.4±3.4 mV to
+5.9±9.8 mV. This current demonstrated instantaneous activation following voltage steps and increased slightly in amplitude over the course of a 100-millisecond pulse (Fig. 2B). There was no significant change in reversal potential or mean current at +100 mV when recording with extracellular Na\(^+\) methanesulphonate (162.2±62.1 pA, n=4, p=0.89) or N-methyl-D-glucamine (NMDG) Cl\(^-\) (180±48.2 pA, n=7, p=0.61) rather than NaCl, and there was no change when recording with intracellular Cs\(^{2+}\) glutamate (142.0±36.3 pA, n=4, p=0.928) rather than KCl. However, replacing intracellular K\(^+\) with N-methyl-D-glucamine markedly reduced the outward current at +100 mV (31.7±6.0 pA, n=6, p=0.0013) but did not alter the reversal potential (Vm 5.8±3.5 mV, p=0.99). The ions carried by this current are therefore non-selective cations. Lastly, the selective adenosine A\(_{2A}\) receptor agonist CGS21680 did not induce this outward current, and the current was still inducible in the presence of the selective A\(_{2A}\) and A\(_{2B}\) receptor antagonists ZM241385 [33] (120.6±52.6 pA at +100 mV, n=5, p=0.56) and MRS1754 [34] (160.2±66.9 pA at +100 mV, n=5, p=0.91), respectively. Taken together this suggests that induction of this non-selective cation current does not involve the A\(_{2A}\) or A\(_{2B}\) adenosine receptors.
Adenosine closes KCa3.1 in the presence of the specific KCa3.1 opener 1-EBIO

We next examined whether adenosine closes KCa3.1 at concentrations that inhibit IgE-dependent degranulation. Because adenosine might potentially inhibit many cell activation pathways that could reduce cytosolic free Ca^{2+} and thus reduce KCa3.1 activity indirectly, we concentrated on studying the effects of adenosine on KCa3.1 currents that were induced by the KCa3.1 opener 1-ethyl-2-benzimidazolinone (1-EBIO). This compound opens KCa3.1 with a half-maximal value of about 30 μM for heterologously expressed KCa3.1, with a maximal effect at about 300 μM [35]. The effects of 1-EBIO are relatively specific for KCa3.1, opening it by enhancing its sensitivity to [Ca^{2+}]_i [35]. Thus at 100 μM 1-EBIO, maximal K^+ currents are achieved in the presence of 100 nM free Ca^{2+}, which is below the resting [Ca^{2+}]_i of most cell types, including HLMC [15].

At concentrations of 10^{-6} M and below, adenosine had little or no effect on KCa3.1 currents that had been activated by 1-EBIO. However, addition of adenosine (10^{-5} to 10^{-3} M) to cells in which KCa3.1 had been activated by 1-EBIO produced a rapid dose-responsive inhibition of channel activity with an associated positive shift in membrane potential (Fig. 3A). Adenosine at 10^{-4} M suppressed the KCa3.1 current in >90% of cells (Fig. 4A). Thus addition of 10^{-4} M adenosine reduced KCa3.1 membrane current at +40 mV from 169.3±16.1 to 84.8±12.6 pA (n=49 cells, p<0.0001)(Fig. 4A), with a corresponding shift in reversal potential (Vm) from -61.0±1.3 to -35.1±4.0 mV (p<0.0001) (Fig. 4B). The IC_{50} of KCa3.1 by adenosine occurred at 30.9±12.7 μM (calculated from 5 cells). Importantly, the effect of adenosine was partially reversed within 1 min by removing it from the recording solution (current post-adenosine 90±41 pA, post-wash 131±39 pA, n=7, p=0.035; Vm post-adenosine −34.0±7.3 mV, post-wash −40±5.5 mV, p=0.095) (Figure 3B, C and 4C, D), indicating that non-specific “run-down” was not responsible for the effects seen. Because the outwardly rectifying current described above rapidly faded, this did not interfere with analysis of the KCa3.1 current.

KCa3.1 modulation by adenosine is mediated via A2A but not A2B receptors

To confirm that the effects of adenosine were mediated via adenosine receptors, we examined the effects of A2A and A2B receptors agonists/antagonists. The suppression of KCa3.1 by adenosine was partially reversed by the competitive A_{2A} receptor antagonist ZM241385 (Fig. 5A–C). Thus in experiments studying ZM241385 at a concentration of 10^{-6} M, current at +40 mV was 32.5±12.2 pA post-adenosine, increasing to 83.4±24.4 pA post-ZM241385 (p=0.048, n=11 cells)(Fig. 5B). There were parallel shifts in reversal potential (Vm post-adenosine −22.3±10.1 mV, post-ZM241385 −39.5±8.4 mV, p=0.007) (Fig. 5C). However, unlike the β_{2}-adrenoceptor inverse agonist ICI 118551 [18], ZM241385 did not open KCa3.1 on its own (data not shown, n=10 cells tested). The effects of adenosine on the KCa3.1 current were not mediated via the A_{2B} receptor, as the selective A_{2B} receptor antagonist MRS1754 (up to 10^{-6} M) did not reverse the suppressive effects of adenosine (in fact there was a further small but
significant decline in current amplitude) (Fig. 5D, E). When comparing the effects of ZM241385 with MRS1754 regarding their ability to reverse the adenosine-suppressed KCa3.1 current, there was a highly significant difference (p=0.008).

In further support of the A2A adenosine receptor coupling to the KCa3.1 channel, the selective A2A receptor agonist CGS21680 mimicked the effects of native adenosine in a dose-dependent and partially reversible manner (Fig. 6). At a concentration of 10^{-6} M, CGS21680 reduced the KCa3.1 current from 118.8±24.1 pA to 97.4±21.8 pA (p=0.007, n=9).

Lastly, we confirmed that the adenosine-dependent regulation of KCa3.1 was relevant to KCa3.1 channels that had been opened by anti-IgE-dependent activation. Anti-IgE (1:1000 dilution) opened KCa3.1 in 6/6 cells tested (baseline current at +40 mV 17.5±7.3 pA, baseline Vm = -34.5±8.0 mV; post anti-IgE current 81.5±18.0 pA, Vm = -62.3±2.5 mV). Adenosine (10^{-4} M) suppressed the current to 49.3±12.6 pA (p=0.007) and produced an associated positive shift in Vm (−49.2±6.5 mV, p=0.046). This suppressive effect of adenosine was partially reversed by ZM241385 (current 75.6±19.8 pA, p=0.050; Vm = 58.5±4.8 mV, p=0.020) (Fig. 7).

Adenosine inhibits HLMC migration

Conditioned medium from asthmatic airway smooth muscle that has been activated with TNF-α, IFN-γ and IL-1β mediates HLMC chemotaxis predominantly via the CXCL10/CXCR3 pathway, with additional contributions from ligands for CXCR1 and CXCR3 [36]. Inhibition of KCa3.1 by channel blockers markedly suppresses this HLMC chemotaxis [17]. Migration of HLMC using conditioned medium from asthmatic airway smooth muscle was 2.0±0.7-fold higher than in the presence of control medium (n=5, p=0.029), and this was almost completely abrogated by adenosine, with a calculated IC_{50} of 2.5±0.8 μM (Fig. 8A). This inhibitory effect of adenosine on HLMC migration utilised the A2A adenosine receptor, as it was blocked by the A2A receptor antagonist ZM241385 (10^{-6} M) (n=3, p=0.010) (Fig. 8B).

Discussion

In this study we have tested the novel hypothesis that modulation of HLMC activation by adenosine interferes with ion channel function in these cells. We show for the first time that adenosine closes the KCa3.1 K+ channel via the Gαs-coupled A2A adenosine receptor and that, as predicted from this effect, adenosine markedly attenuates HLMC migration. Since opening of the KCa3.1 K+ channel potentiates Ca^{2+} influx and histamine secretion [14] and its blockade almost abolishes chemotactic responses [17], the ability of adenosine to close this channel provides a potential mechanism directly linking A2A receptor engagement with diminished secretion and migration.

Adenosine closed KCa3.1 following IgE-dependent activation, but it was possible that this effect might occur indirectly through the perturbation of complex intracellular signalling pathways. We therefore used the
KCa3.1 opener 1-EBIO to activate the channel rather than IgE-dependent activation. Since 1-EBIO opens KCa3.1 in resting cells by increasing its affinity for Ca²⁺ [35], it is particularly interesting that adenosine closes KCa3.1 under these conditions. This effect of adenosine was reversed both by removing it from the recording solution and by the addition of the competitive A₂A adenosine receptor antagonist ZM241385, indicating a receptor-mediated mechanism. Since the effects of adenosine were not antagonised by the A₂B receptor antagonist MRS1754 but were mimicked by the A₂A receptor agonist CGS21680, we have firm evidence that the suppression of KCa3.1 by adenosine is mediated via the A₂A adenosine receptor.

The ability of adenosine to close KCa3.1 is in keeping with our previous observations that this channel is closed by the Gαs-coupled β₂-adrenoceptor [18]. These effects of both A₂A adenosine and β₂-adrenoceptor activation on KCa3.1 are not mimicked by cAMP analogues or the activator of adenylate cyclase forskolin [18], indicating that the most likely mechanism is membrane-delimited involving the Gαs or βγ subunits of these GPCR. This is further suggested by the fact that adenosine (and β₂-receptor agonists) modulate KCa3.1 in the whole-cell configuration of patch-clamp recording. This mode of recording dialyses the cell and depletes soluble intracellular second messengers, indicating that the adenosine A₂A receptor and KCa3.1 channel are likely to be coupled tightly in a membrane-restricted signalplex.

Several molecules that attenuate HLMC secretion, including adenosine and β₂-adrenoceptor agonists, increase intracellular cAMP. It is this increase in intracellular cAMP that has been thought to couple to inhibition of secretion, but there is no mechanism to explain this. However, the exclusive role of cAMP in the inhibition of mast cell degranulation and promotion of smooth muscle relaxation has recently been challenged [37, 38]. We have shown previously that opening of KCa3.1 enhances IgE-dependent Ca²⁺ influx and degranulation [15] and that its blockade attenuates this [14]. Thus the demonstration that adenosine closes KCa3.1 provides for the first time a clearly defined mechanism by which adenosine A₂A receptor stimulation can be linked to attenuated secretion.
The migration and re-location of mast cells within tissues is important for their effector function in a number of diseases [10, 39, 40]. For example in asthma, the role of mast cells in the disordered airway physiology is facilitated by their migration into the airway epithelium [41], submucosal glands [11] and airway smooth muscle [10]. Inhibition of their migration and subsequent microlocalisation within these structures is therefore an attractive therapeutic target. Blockade of KCa3.1 markedly inhibits HLMC migration in response to a number of diverse chemotactic stimuli, including conditioned medium from activated asthmatic airway smooth muscle [17]. The ability of adenosine to close KCa3.1 suggested it should also inhibit HLMC migration, which was indeed the case. Adenosine was slightly more potent at inhibiting migration (IC50 ~ 3 μM) than closing KCa3.1 (IC50 ~ 31 μM) or inhibiting mediator release (IC50 ~ 74 μM). These results regarding migration versus degranulation are consistent with the observation that HLMC migration is also far more sensitive to direct KCa3.1 blockade than degranulation [14, 17]. Migration appears particularly sensitive to KCa3.1 blockade, because even a partial block markedly inhibits oscillations in KCa activity, which in turn prevents the changes in cell volume that are required

![Figure 6](image6.png)  
**Figure 6.** The effect of an adenosine A2A receptor agonist on KCa3.1 currents in HLMC. (A) Current-voltage curve demonstrating dose-dependent suppression of a 1-EBIO-induced KCa3.1 current by the A2A Receptor agonist CGS21680 and (B) reversibility of this suppression following its removal (wash).

![Figure 7](image7.png)  
**Figure 7.** The effect of adenosine on KCa3.1 currents elicited by anti-IgE-dependent mast cell activation. Data from a representative HLMC showing KCa3.1 current opening following anti-IgE-dependent activation, suppression of this by adenosine and reversal of the adenosine-induced suppression by the adenosine A2A receptor antagonist ZM241385.

![Figure 8](image8.png)  
**Figure 8.** Inhibition of HLMC chemotaxis by adenosine. (A) Conditioned medium from asthmatic airway smooth muscle (ASM) was used as the chemotactic stimulus. Data represents the mean ± SEM from five individual HLMC donors (*p<0.005). (B) Inhibition of HLMC migration by adenosine is prevented by the A2A receptor antagonist ZM241385. Data represents the mean ± SEM from three individual HLMC donors.
for migration to proceed [42, 43]. This is further supported by the observation that in addition to blocking of KCa3.1, permanently opening it with 1-EBIO also inhibits migration [44]. However, the relative sensitivity of migration to adenosine versus KCa3.1 closure might also suggest that the effects of adenosine on migration operate through additional mechanisms, such as generation of cAMP. However, the experimental conditions are also likely to account for some of this difference. This is because we can only reliably patch-clamp HL-MC at temperatures up to 27°C [14], which will likely slow down the kinetics and magnitude of any agonist effect, and we have also recorded currents in the whole-cell configuration, which dials the cell, resulting in the loss of potentially important signalling components. In contrast, cell migration and mediator release assays are performed in intact cells at 37°C.

Previous studies have suggested that at lower concentrations (approximately 10^{-6} M), adenosine actually promotes mediator release from human mast cells [23–27]. However, the magnitude of this effect and the concentrations of adenosine required to produce it have been highly varied [23–27, 29], and a recent study investigating cord blood-derived human mast cells did not find any potentiating effect [30]. Adenosine did not potentiate degranulation from HL-MC in our hands, which is in keeping with a failure to detect any modulation of ion channel activity, such as opening of KCa3.1 either directly or indirectly through initiation of Ca^{2+} influx, which might be predicted to enhance secretion. Interestingly, in rodent mast cells, adenosine opens an outwardly rectifying K^+ channel that is not Ca^{2+}-activated, is distinct from KCa3.1 and has been proposed to account for the ability of adenosine to enhance mediator release in these cells [45, 46]. We did not see this channel in HL-MC, which is yet another example of the important heterogeneity evident in the biology of human and rodent mast cells [47].

In addition to its effects on KCa3.1, adenosine at relatively high concentrations opened a novel and transient outwardly rectifying ion channel that was indirectly demonstrated to carry non-selective cations. Interestingly, this current still appeared in the presence of the adenosine A2A and A2B receptor antagonists, suggesting that it is mediated through another pathway. Because this outwardly rectifying current depolarises the cells (and would therefore be predicted to attenuate Ca^{2+} influx) and occurs at concentrations of adenosine that attenuate degranulation, it is possible that this channel also inhibits mast cell mediator release. The transient nature of this current might be due to “run-down” caused by the depletion of intracellular second messengers induced by whole-cell recording, but we believe that this is unlikely due to the very rapid nature by which the current diminishes. However, it will be important that this is analysed in more detail using the perforated patch mode of recording.

In vivo, adenosine induces airway narrowing in asthmatic subjects, with evidence that this results from mast cell degranulation [20, 21]. This effect is thought to be mediated directly via the A2B adenosine receptor on mast cells, although this is not proven, and might also involve indirect mechanisms [28, 32]. Adenosine A2B receptor antagonists are therefore being considered as novel therapies for asthma. An alternative strategy is to target the anti-inflammatory A2A receptor with specific agonists delivered locally to the airway [48, 49]. Drugs that block KCa3.1 are also in development as anti-inflammatory treatments [13]. Our demonstration that the A2A adenosine receptor closes KCa3.1 in HL-MC therefore provides further support for the development of specific A2A adenosine receptor agonists for the treatment of mast cell-mediated disease.

Materials and methods

Reagents

We used the following reagents: stem cell factor (SCF), IL-6 and IL-10 (R&D, Abingdon, UK); goat polyclonal anti-human IgE, adenosine, CGS21680, ZM241385, MRS1754 (Sigma, Poole, Dorset, UK); 1-ethyl-2-benzimidazolinone (1-EBIO) (Tocris, Avonmouth, UK); human myeloma IgE (Calbiochem-Novabiochem, Nottingham, UK); mouse IgG1 mAb YB5B8 (anti-CD117) (Cambridge Bioscience, Cambridge, UK); sheep anti-mouse IgG1 Dynabeads (Dynal, Wirral, UK); Dulbecco’s Modified Essential Medium (DMEM)/glutamax/Hepes, antibiotic/antimycotic solution, MEM nonessential amino acids and FCS (Life Technologies, Paisley, Scotland, UK).

Human mast cell purification and culture

All human subjects gave written informed consent, and the study was approved by the Leicestershire Research Ethics Committee. HL-MC were dispersed and purified from macroscopically normal lung (n=11 donors) obtained within 1 h of resection for lung cancer using immunomagnetic affinity selection as described previously [50]. Final mast cell purity was >99%, and viability was >97%. HL-MC were cultured in DMEM/glutamax/Hepes containing antibiotic/antimycotic solution, nonessential amino acids, 10% FCS, 100 ng/mL SCF, 50 ng/mL IL-6 and 10 ng/mL IL-10 for up to 10 wks as described previously [15, 51].

HL-MC activation

For analysis of histamine release, 1×10^4 mast cells were warmed to 37°C in triplicate in 50 μL DMEM. Adenosine (±ZM241385 or DMSO control) at 4× the final concentration in 25 μL DMEM was added just prior to addition of 25 μL DMEM containing 4× the final concentration of goat polyclonal anti-human IgE (1:1000 final dilution) gives maximal histamine
release, 1:30 000 final dilution gives sub-maximal histamine release) [15]. After 30 min incubation at 37°C, the cells were centrifuged at 250 × g for 4 min, the supernatant decanted and control cell pellets lysed in sterile deionised water for measurement of total histamine content as described previously [50]. The final DMSO concentration was 0.1%.

Electrophysiology

The whole-cell variant of the patch-clamp technique was used [14, 52]. Patch pipettes were made from borosilicate fiber-containing glass (Clark Electromedical Instruments, Reading, UK), and their tips were heat-polished, typically resulting in resistances of 4–6 MΩ. The standard pipette solution contained 140 mM KCl, 2 mM MgCl₂, 10 mM Hepes, 2 mM Na⁺-ATP and 0.1 mM GTP, pH 7.3. The standard external solution contained 140 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂ and 10 mM Hepes, pH 7.3. For recording, mast cells were placed in 35-mm dishes containing standard external solution. Whole-cell currents were recorded using an Axoclamp 200 A amplifier (Axon Instruments, Foster City, CA, USA), and currents were evoked by applying voltage commands to a range of potentials in 10 mV steps from a holding potential of –20 mV. The currents were digitized (sampled at a frequency of 10 kHz), stored on computer and subsequently analyzed using pClamp software (Axon Instruments). Capacitance transients were minimized using the capacitance neutralization circuits on the amplifier. Correction for series resistance was not routinely applied. Experiments were performed at 27°C, with the temperature controlled by a Peltier device. Experiments were performed with a perfusion system (Automate Scientific, San Francisco, CA) to allow solution changes, although drugs were added directly to the recording chamber.

HLMC chemotaxis

HLMC chemotaxis assays were performed using the Transwell system (BD Biosciences, Oxford, UK) with 24-well plates as described previously [17, 36]. Conditioned medium from asthmatic airway smooth muscle that had been activated with TNF-α, IL-1β and IFN-γ was placed in the lower wells as described previously [36], with appropriate cytokine-containing medium in the negative control. Adenovise was added to the bottom wells in the concentration range 10⁻⁶–10⁻³ M, and 1 × 10⁵ HLMC in 100 μl were added to the top well. After incubating the cells for 3 h at 37°C, we counted the number of HLMC in the bottom well using Kimura stain in a haemocytometer. HLMC migration was calculated as the fold increase of migrated cells in the test wells compared to the negative control (no chemotaxtractant in the lower well) as described previously [17, 36].

Data presentation and statistical analysis

Data are expressed as mean ± SEM unless otherwise stated. Differences between groups of data were explored using Student’s paired or unpaired t-test (two-tailed) as appropriate.

Acknowledgements: This work was supported by the Wellcome Trust (grant number 076264). We thank Amanda Sutcliffe for technical support.

References

1. Bradding, P. and Holgate, S. T., Immunopathology and human mast cell cytokines. Crit. Rev. Oncol. Haematol. 1999. 31: 119–133.
2. Bradding, P., The role of the mast cell in asthma: a reassessment. Curr. Opin. Allergy Clin. Immunol. 2003. 3: 45–50.
3. Bradding, P., Walls, A. F. and Holgate, S. T., The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 2006. 117: 1277–1284.
4. Coward, W. R., Okayama, Y., Sagara, H., Wilson, S. J., Holgate, S. T. and Church, M. K., NF-κappa B and TNF-alpha: a positive autocrine loop in human lung mast cells? J. Immunol. 2002. 169: 5287–5293.
5. Redegeld, F. A., van der Heijden, M. W., Kool, M., Heijdra, B. M., Garsen, J., Kraneveld, A. D., Van, L. H. et al., Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat. Med. 2002. 8: 694–701.
6. McCurdy, J. D., Olynch, T. J., Maher, L. H. and Marshall, J. S., Cutting edge: Distinct Toll-like receptor 2 activators selectively induce different classes of mediator production from human mast cells. J. Immunol. 2003. 170: 1625–1629.
7. Kulkka, M., Alexeopoulou, L., Flavell, R. A. and Metcalfe, D. D., Activation of mast cells by double-stranded RNA: evidence for activation through Toll-like receptor 3. J. Allergy Clin. Immunol. 2004. 114: 174–182.
8. Supapajatra, V., Ushio, H., Nakao, A., Akira, S., Okumura, K., Ra, C. and Ogawa, H., Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity. J. Clin. Invest. 2002. 109: 1351–1359.
9. Machado, D. C., Horton, D., Harrop, R., Peachell, P. T. and Helm, B. A., Potential allergens stimulate the release of mediators of the allergic response from cells of mast cell lineage in the absence of sensitization with antigen-specific IgE. Eur. J. Immunol. 1996. 16: 2972–2980.
10. Brightling, C. E., Bradding, P., Symon, F. A., Holgate, S. T., Wardlaw, A. J. and Pavord, I. D., Mast cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 2002. 346: 1699–1705.
11. Carroll, N. G., Mutavdzic, S. and James, A. L., Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma. Thorax 2002. 57: 677–682.
12. Bradding, P., Mast cell ion channels. Chem. Immunol. Allergy 2005. 87: 163–178.
13. Chandy, K. G., Wulff, H., Beeton, C., Pennington, M., Gutman, G. A. and Cahalan, M. D., Ion channels in mast cells. Adv. Physiol. Sci. 2004. 163–178.
14. Duffy, S. M., Lawley, W. J., Conley, E. C. and Bradding, P., Resting and activation-dependent ion channels in human mast cells. J. Immunol. 2001. 167: 4261–4270.
15. Duffy, S. M., Berger, P., Cruse, G., Yang, W., Bolton, S. J. and Bradding, P., The K⁺ channel IKCa1 potentiates Ca²⁺ influx and degranulation in human lung mast cells. J. Allergy Clin. Immunol. 2004. 114: 66–72.
16. Hoth, M. and Penner, R., Depletion of intracellular calcium stores activates a calcium current in mast cells. Nature 1992. 355: 353–356.
17. Cruse, G., Duffy, S. M., Brightling, C. E. and Bradding, P., Functional KCa3.1 K⁺ channels are required for human mast cell migration. Thorax 2006. 61: 880–885.
18. Duffy, S. M., Cruse, G., Lawley, W. J. and Bradding, P., Beta2-adrenoceptor regulation of the K⁺ channel IKCa1 in human mast cells. FASEB J. 2005. 19: 1006–1008.
19. Driver, A. G., Kukoly, C. A., Ali, S. and Mustafa, S. J., Adenosine in bronchoalveolar lavage fluid in asthma. Am. Rev. Respir. Dis. 1993. 148: 91–97.
20. Polosa, R., Adenosine-receptor subtypes: their relevance to adenosine-mediated responses in asthma and chronic obstructive pulmonary disease. Eur. Respir. J. 2002. 20: 488–496.
1662

S. Mark Duffy et al.

Eur. J. Immunol. 2007. 37: 1653–1662

21 Holgate, S. T., The Quintiles Prize Lecture 2004: The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br. J. Pharmacol. 2005. 149: 1005–1015.

22 Feoktistov, I., Biaggioni, I., Polosa, R. and Holgate, S. T., Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol. Sci. 1998. 19: 148–153.

23 Peters, S. P., Schultman, E. S., Schleimer, R. P., MacGlashan, D. W. Jr., Newball, H. H. and Lichtenstein, L. M., Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. Am. Rev. Respir. Dis. 1982. 126: 1034–1039.

24 Hughes, P. J., Holgate, S. T. and Church, M. K., Adenosine inhibits and potentiates IgE-dependent histamine release from human lung mast cells by an A2a-purinoceptor mediated mechanism. Biochem. Pharmacol. 1984. 33: 3847–3852.

25 Peachell, P. T., Lichtenstein, L. M. and Schleimer, R. P., Differential regulation of human basophil and lung mast cell function by adenosine. J. Pharmacol. Exp. Ther. 1991. 256: 717–726. Erratum in: J. Pharmacol. Exp. Ther. 1991. 257: 539.

26 Peachell, P. T., Columbus, M., Kagey-Sobotka, A., Lichtenstein, L. M. and Marone, G., Adenosine potentiates mediator release from human lung mast cells. Am. Rev. Respir. Dis. 1988. 138: 1143–1151.

27 Schulman, E. S., MacGlashan, D. W. Jr., Peters, S. P., Schleimer, R. P., Newball, H. H. and Lichtenstein, L. M., Human lung mast cells: purification and characterization. J. Immunol. 1982. 129: 2662–2667.

28 Feoktistov, I., Garland, E. M., Goldstein, A. E., Zeng, D., Belardelli, L., Wells, J. N. and Biaggioni, I., Inhibition of human mast cell activation with the novel selective adenosine A2B receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPX). Biochem. Pharmacol. 2001. 62: 1163–1173.

29 Schulman, E. S., Graum, M. C., Post, T., Wang, Y., Raible, D. G., Mohanty, J., Butterfield, J. H. and Pellegr, A., ATP modulates anti-IgE-induced release of histamine from human lung mast cells. J. Clin. Invest. 1994. 93: 530–537.

30 Suzuki, H., Takei, M., Nakahata, T. and Fukamachi, H., Inhibitory effect of adenosine on degranulation of human cultured mast cells upon cross-linking of Fc[epsilon]RI. Biochem. Biophys. Res. Comm. 1998. 242: 697–702.

31 Polosa, R., Ng, W. H., Crimi, N., Vancheri, C., Holgate, S. T., Church, M. K. and Mestrellia, R., Release of mast-cell-derived mediators after endobronchial adenosine challenge in asthma. Am. J. Respir. Crit. Care Med. 1995. 151: 624–629.

32 Keir, S., Boswell-Smith, V., Spina, D. and Page, C., Mechanism of adenosine-induced airways obstruction in allergic guinea pigs. Br. J. Pharmacol. 2006. 147: 720–728.

33 Palmer, T. M., Poucher, S. M., Jacobson, K. A. and Stiles, G. L., 125I-[2-[7-amino-2-(2-furyl)]-[4H]-triazolo[2, 3-a][3, 4]triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol. Pharmacol. 1995. 48: 970–974.

34 Ji, X., Kim, Y. C., Ahern, D. G., Linden, J. and Jacobson, K. A., [3H]MRSA 1754, a selective antagonist radioligand for A2B adenosine receptors. Biochem. Pharmacol. 2001. 61: 657–663.

35 Pedersen, K. A., Schroder, R. L., Skaaning-Jensen, B., Strobaek, D., Olesen, S. P. and Christophsersen, P., Activation of the human intermediate-conductance Ca(2+)-activated K(+) channel by 1-ethyl-2-benzimidazolone is strongly Ca(2+)-dependent. Biochim. Biophys. Acta 1999. 1420: 231–240.

36 Brightling, C. E., Ammit, A. J., Kaur, D., Black, J. L., Wardlaw, A. J., Hughes, J. M. and Bradding, P., The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am. J. Respir. Crit. Care Med. 2005. 171: 1103–1108.

37 Tsuji, T., Kato, T., Kimata, M., Serizawa, I., Inagaki, N. and Nagai, H., Differential effects of beta2-adrenoceptor desensitization on the IgE-dependent release of chemical mediators from cultured human mast cells. Biol. Pharm. Bull. 2004. 27: 1549–1554.

38 Kume, H., Hall, I. P., Washabau, R. J., Takagi, K. and Kotlikoff, M. I., Beta-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms. J. Clin. Invest. 1994. 93: 371–379.

39 Inoue, Y., King, T. E. J., Tinkle, S. S., Dockstader, K. A. and Newman, L. S., Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am. J. Pathol. 1996. 149: 2037–2054.

40 Gotis-Graham, I. and McNeel, H. P., Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum. 1997. 40: 479–489.

41 Bradding, P., Roberts, J. A., Britten, K. M., Montefort, S., Dijkmanovic, R., Mueller, R., Heusser, C. H. et al., Interleukin-4, –5, –6 and –7 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol. 1994. 10: 471–480.

42 Schwab, A., Wijnowski, L., Gabriel, K. and Oberleithner, H., Oscillating activity of a Ca2+-sensitive K+ channel. A prerequisite for migration of transformed Madin-Darby canine kidney focus cells. J. Clin. Invest. 1994. 93: 1631–1636.

43 Danker, T., Gassner, B., Oberleithner, H. and Schwab, A., Extracellular detection of K+ release during migration of transformed Madin-Darby canine kidney cells. Pfluegers Arch. 1996. 433: 71–76.

44 Schwab, A., Schuricht, B., Seeger, P., Reinhardt, J. and Dartsch, P. C., Migration of transformed renal epithelial cells is regulated by K+ channel modulation of actin cytoskeleton and cell volume. Pfluegers Arch. 1999. 438: 330–337.

45 Qian, Y. X. and McCloskey, M. A., Activation of mast cell K+ channels through multiple G protein-linked receptors. Proc. Natl. Acad. Sci. USA 1993. 90: 7844–7848.

46 McCloskey, M. A. and Qian, Y. X., Selective expression of potassium channels during mast cell differentiation. J. Biol. Chem. 1994. 269: 14813–14819.

47 Church, M. K., Okayaama, Y. and Bradding, P., Functional mast cell heterogeneity. In Busse, W. W. and Holgate, S. T. (Eds.) Asthma and Rhinitis. Blackwell Scientific Publications, Inc, Boston 1994, pp. 209–220.

48 Fozard, J. R. and McCarthy, C., Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Investig. Drugs 2002. 3: 69–77.

49 Fozard, J. R., Ellis, K. M., Villela Danses, M. F., Tiganie, B. and Mazzoni, L., Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur. J. Pharmacol. 2002. 438: 183–188.

50 Sanmugalingam, D., Wardlaw, A. J. and Bradding, P., Adhesion of human lung mast cells to bronchial epithelium: evidence for a novel carbohydrate-mediated mechanism. J. Leuk. Biol. 2000. 68: 38–46.

51 Duffy, S. M., Lawley, W. J., Kaur, D., Yang, W. and Bradding, P., Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation. J. Allergy Clin. Immunol. 2003. 112: 970–977.

52 Hamill, O. P., Marty, A., Neher, E., Sakmann, B. and Sigworth, F. J., Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pfluegers Arch. 1981. 391: 85–100.